Sun Pharmaceutical Industries Limited (BOM:524715)
India
· Delayed Price · Currency is INR 1,807.60
+8.65 (0.48%)
At close: Mar 9, 2026
BOM:524715 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Revenue | 568,091 | 525,784 | 484,969 | 438,857 | 386,545 | 334,981 | Upgrade
|
| Revenue Growth (YoY) | 10.09% | 8.42% | 10.51% | 13.53% | 15.39% | 2.01% | Upgrade
|
| Cost of Revenue | 121,909 | 115,585 | 114,422 | 113,187 | 108,761 | 92,185 | Upgrade
|
| Gross Profit | 446,182 | 410,200 | 370,547 | 325,670 | 277,784 | 242,796 | Upgrade
|
| Selling, General & Admin | 110,247 | 100,509 | 95,025 | 83,549 | 73,544 | 69,042 | Upgrade
|
| Other Operating Expenses | 171,102 | 157,883 | 144,755 | 123,779 | 101,331 | 88,678 | Upgrade
|
| Operating Expenses | 309,611 | 284,145 | 265,345 | 232,613 | 196,223 | 178,520 | Upgrade
|
| Operating Income | 136,572 | 126,055 | 105,202 | 93,058 | 81,560 | 64,276 | Upgrade
|
| Interest Expense | -3,022 | -2,314 | -2,385 | -1,720 | -1,274 | -1,414 | Upgrade
|
| Interest & Investment Income | 12,970 | 12,970 | 11,262 | 5,310 | 7,687 | 4,672 | Upgrade
|
| Earnings From Equity Investments | -485.2 | -153.5 | -384.1 | -479 | -165.4 | -123.3 | Upgrade
|
| Currency Exchange Gain (Loss) | 11,047 | 1,855 | 361.3 | -1,261 | 1,540 | 236.5 | Upgrade
|
| Other Non Operating Income (Expenses) | 2,231 | 620.6 | 546.7 | 756.5 | 735.9 | 2,895 | Upgrade
|
| EBT Excluding Unusual Items | 159,313 | 139,034 | 114,603 | 95,664 | 90,084 | 70,542 | Upgrade
|
| Merger & Restructuring Charges | -3,617 | -3,617 | -739.5 | -643.9 | -563.5 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 5,117 | 5,117 | 921.9 | -240.3 | 7.7 | 260 | Upgrade
|
| Gain (Loss) on Sale of Assets | -164 | -164 | -99.7 | 75.4 | 347.5 | 138.8 | Upgrade
|
| Asset Writedown | -1,586 | -71.3 | -1,564 | -312.5 | -2,179 | -155.5 | Upgrade
|
| Legal Settlements | -58.2 | -58.2 | - | - | -1,563 | -895.6 | Upgrade
|
| Other Unusual Items | -11,502 | -3,104 | -2,712 | -1,071 | -41,657 | -42,166 | Upgrade
|
| Pretax Income | 147,734 | 137,368 | 110,495 | 93,605 | 44,648 | 27,870 | Upgrade
|
| Income Tax Expense | 38,205 | 27,720 | 14,395 | 8,476 | 10,755 | 5,147 | Upgrade
|
| Earnings From Continuing Operations | 109,529 | 109,648 | 96,100 | 85,129 | 33,893 | 22,724 | Upgrade
|
| Minority Interest in Earnings | -376.5 | -357.1 | -336.5 | -393.6 | -1,166 | 6,315 | Upgrade
|
| Net Income | 109,153 | 109,290 | 95,764 | 84,736 | 32,727 | 29,038 | Upgrade
|
| Net Income to Common | 109,153 | 109,290 | 95,764 | 84,736 | 32,727 | 29,038 | Upgrade
|
| Net Income Growth | -4.54% | 14.12% | 13.01% | 158.92% | 12.70% | -22.87% | Upgrade
|
| Shares Outstanding (Basic) | 2,401 | 2,399 | 2,399 | 2,399 | 2,399 | 2,399 | Upgrade
|
| Shares Outstanding (Diluted) | 2,401 | 2,399 | 2,399 | 2,399 | 2,399 | 2,399 | Upgrade
|
| Shares Change (YoY) | 0.24% | - | - | - | - | - | Upgrade
|
| EPS (Basic) | 45.45 | 45.55 | 39.91 | 35.32 | 13.64 | 12.10 | Upgrade
|
| EPS (Diluted) | 45.45 | 45.55 | 39.90 | 35.30 | 13.60 | 12.10 | Upgrade
|
| EPS Growth | -4.73% | 14.16% | 13.03% | 159.56% | 12.40% | -22.89% | Upgrade
|
| Free Cash Flow | - | 119,435 | 99,332 | 28,738 | 74,895 | 50,002 | Upgrade
|
| Free Cash Flow Per Share | - | 49.78 | 41.40 | 11.98 | 31.21 | 20.84 | Upgrade
|
| Dividend Per Share | 16.500 | 16.000 | 13.500 | 11.500 | 10.000 | 7.500 | Upgrade
|
| Dividend Growth | 6.45% | 18.52% | 17.39% | 15.00% | 33.33% | 87.50% | Upgrade
|
| Gross Margin | 78.54% | 78.02% | 76.41% | 74.21% | 71.86% | 72.48% | Upgrade
|
| Operating Margin | 24.04% | 23.97% | 21.69% | 21.20% | 21.10% | 19.19% | Upgrade
|
| Profit Margin | 19.21% | 20.79% | 19.75% | 19.31% | 8.47% | 8.67% | Upgrade
|
| Free Cash Flow Margin | - | 22.72% | 20.48% | 6.55% | 19.38% | 14.93% | Upgrade
|
| EBITDA | 160,246 | 149,679 | 128,760 | 116,513 | 101,536 | 83,451 | Upgrade
|
| EBITDA Margin | 28.21% | 28.47% | 26.55% | 26.55% | 26.27% | 24.91% | Upgrade
|
| D&A For EBITDA | 23,674 | 23,625 | 23,559 | 23,456 | 19,975 | 19,175 | Upgrade
|
| EBIT | 136,572 | 126,055 | 105,202 | 93,058 | 81,560 | 64,276 | Upgrade
|
| EBIT Margin | 24.04% | 23.97% | 21.69% | 21.20% | 21.10% | 19.19% | Upgrade
|
| Effective Tax Rate | 25.86% | 20.18% | 13.03% | 9.05% | 24.09% | 18.47% | Upgrade
|
| Revenue as Reported | 589,352 | 545,435 | 498,510 | 445,202 | 395,760 | 343,337 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.